<DOC>
	<DOCNO>NCT00679445</DOCNO>
	<brief_summary>The objective clinical study evaluate safety feasibility focal delivery radiation treatment subfoveal choroidal neovascularization ( CNV ) patient age relate macular degeneration fail Primary Anti-VEGF therapy .</brief_summary>
	<brief_title>A Study Evaluate Neovista Ophthalmic System Treatment Subfoveal CNV Patients With AMD That Have Failed Primary Anti-VEGF Therapy</brief_title>
	<detailed_description>Therapeutic advance arena neovascular age-related macular degeneration ( AMD ) provide multiple treatment option disease . Radiotherapy study multiple clinical trial past many study show therapeutic benefit . Treatment radiotherapy anti-VEGF compound promise approach treat AMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects must predominantly classic , minimally classic , occult classic lesion , determine Investigator , secondary AMD , total lesion size ( include blood , scar , neovascularization ) &lt; 12 total disc area ( 21.24 mm2 ) , GLD ≤5.4 mm Subjects must receive minimum three ( 3 ) prior injection ( minimum 3 prior injection compound ) antiVEGF therapy ( Lucentis® Avastin® , subject may treat previously Macugen® , must recently treat Lucentis® Avastin® meet criterion failure ) evidence `` failure '' respond therapy Subjects must age 50 old Subjects prior subfoveal CNV therapy photodynamic therapy , intravitreal subretinal steroid , transpupillary thermotherapy ( TTT ) ( Note : This include subject know history , photographic evidence prior therapy ) Subjects underwent previous radiation therapy eye , head neck Subjects previously diagnose Type 1 Type 2 diabetes mellitus . Subjects document diagnosis retinal finding consistent Type 1 Type 2 Diabetes Mellitus . Women childbearing potential ( female subject must post menopausal surgically sterilize )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Macular</keyword>
	<keyword>Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Wet Age-related macular degeneration</keyword>
</DOC>